Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT

Trial Profile

Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2014

At a glance

  • Drugs Amifostine (Primary)
  • Indications Head and neck cancer; Salivary gland disorders; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Washington University School of Medicine
  • Most Recent Events

    • 18 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top